A top US Food and Drug Administration official was frustrated with the pace of the review of Pfizer Inc./BioNTech SE’s COVID-19 vaccine Comirnaty in 2021, and appeared to push for the application to be approved several weeks earlier than staff wanted, agency emails reveal.
The trove of messages released by the agency show Center for Biologics Evaluation and Research Director Peter Marks telling...







